Skip to main content
Clinical Trials/NCT07543926
NCT07543926
Not yet recruiting
Not Applicable

Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts

Sohag University1 site in 1 country70 target enrollmentStarted: April 6, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
70
Locations
1
Primary Endpoint
treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )

Overview

Brief Summary

this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • \- Age more than or equal to 18 years
  • Clinically and dermoscopically confirmed Common warts of both sex
  • patient not receiving previous treatment at least one month before recruitment in our study
  • Single or multiple lesions suitable for injection.

Exclusion Criteria

  • Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .
  • Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .

Arms & Interventions

group 1 PRF injection

Active Comparator

Intervention: PRF group (Biological)

group 2 vitamin D injection

Active Comparator

Intervention: Vitamin D (Drug)

Outcomes

Primary Outcomes

treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )

Time Frame: 1 session every 2 weeks for 3 months

treatment of common wart by intralesional injection of PRF

changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction )

Time Frame: 6 months after the last session

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Bassma Alaaeldin Mohamed

Dermatology , Venerology and Andrology Resident at Sohag University Hospital

Sohag University

Study Sites (1)

Loading locations...

Similar Trials